Paid Clinical Trials Louisiana
Discover 839 paid clinical trials in Louisiana. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
Sponsor:
GB002, Inc.
Location:
Code:
NCT05934526
Conditions
Pulmonary Arterial Hypertension
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Placebo
Seralutinib
Generic Dry Powder Inhaler
Primary Subtalar Arthrodesis for Calcaneal Fractures
Sponsor:
Wake Forest University Health Sciences
Location:
Code:
NCT06249126
Conditions
Calcaneus Fracture
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Primary Fusion (Open Reduction Internal Fixation (ORIF) + Primary Subtalar Arthrodesis (PSTA)
Open Reduction Internal Fixation (ORIF) only
Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney)
Sponsor:
Johns Hopkins University
Location:
Code:
NCT06263426
Conditions
Hiv
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
HIV D+/R+
HIV D-/R+
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
Sponsor:
Biohaven Therapeutics Ltd.
Location:
Code:
NCT06309966
Conditions
Focal Epilepsy
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
BHV-7000
Placebo
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Sponsor:
AstraZeneca
Location:
Code:
NCT06283966
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Eligibility Criteria
Sex: All
Age: 40 - 70+
Healthy Volunteers: Not accepted
Interventions
BGF MDI 320/14.4/9.6 μg
GFF MDI 14.4/9.6 μg
A Study to Investigate the Effect on Lung Function of BDA Formulated With a New Propellant (HFO) Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma
Sponsor:
AstraZeneca
Location:
Code:
NCT06502366
Conditions
Asthma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
BDA MDI HFO 160/180 μg
BDA MDI HFA 160/180 μg
Placebo MDI HFA
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT06393374
Conditions
Triple-Negative Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pembrolizumab
sac-TMT
Capecitabine
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
Sponsor:
Krystal Biotech, Inc.
Location:
Code:
NCT06228326
Conditions
Lung Cancer, Non-small Cell
Lung Cancer Metastatic
Solid Tumor, Adult
Advanced Cancer
Lung Cancer (NSCLC)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
KB707
Pembrolizumab (KEYTRUDA®)
Chemotherapy
Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).
Sponsor:
CinPhloro Pharma, LLC
Location:
Code:
NCT06153420
Conditions
Irritable Bowel Syndrome With Diarrhea
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
CIN-103
Placebo